Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isatuximab,Dexamethasone,Fludarabine Phosphate,Cytarabine,Daunorubicin,Idarubicin Hydrochloride,Filgrastim,Mitoxantrone,Doxorubicin Hydrochloride,Vincristine Sulfate,Peg L asparaginase,Cyclophosphamide,Etoposide,Methotrexate,L - Asparaginase,Hydroxyurea
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 04, 2019
Lead Product(s) : Isatuximab,Dexamethasone,Fludarabine Phosphate,Cytarabine,Daunorubicin,Idarubicin Hydrochloride,Filgrastim,Mitoxantrone,Doxorubicin Hydrochloride,Vincristine Sulfate,Peg L asparaginase,Cyclophosphamide,Etoposide,Methotrexate,L - Asparaginase,Hydroxyurea
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bone Marrow Aspiration,Cytarabine,Hydroxyurea,Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Kura Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Bone Marrow Aspiration,Cytarabine,Hydroxyurea,Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Kura Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Acquisition
Norgine Strengthens Rare Disease Portfolio with Acquisition of Theravia
Details : Through the acquisition, Norgine will have six core products in its rare disease portfolio, which includes Siklos (hydroxyurea) is being indicated for the treatment of sickle cell anemia.
Product Name : Siklos
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
April 15, 2025
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2024
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2022
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Simbec-Orion | Oncodesign | PhinC Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Simbec-Orion | Oncodesign | PhinC Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 11, 2021
Lead Product(s) : Hydroxyurea,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enasidenib,Hydroxyurea
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 IDHENTIFY study evaluating IDHIFA®(enasidenib) plus best supportive care vs conventional care regimens, which include azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint.
Product Name : Idhifa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Enasidenib,Hydroxyurea
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable